禁止リスト2007.indd

2007年禁止リスト国際基準

(The 2007 Prohibited List International Standard)

（2007年１月１日版）

(Update 1 January 2007)

本リストは、2007年１月１日に発効する

財団法人 日本アンチ・ドーピング機構

スポーツ振興くじ助成事業

（The World Anti-doping Code）

世界アンチ・ドーピング規程

仮 訳

WORLD

ANTI-DOPING

AGENCY

play true

ޟWADA code ߪ⧷ᢥ ߇ේᧄߣߥࠅ߹ߔޕᧄⷙ⒟ߩ⧷ᢥߣ๺ᢥߦᏅ⇣

߇޽ࠆ႐วߦߪޔ⧷ᢥ߇ఝవߐࠇ߹ߔޕ

ޠ

THE WORLD ANTI-DOPING CODE

The 2007 Prohibited List International Standard

ଲ ٮ ͺ ϋ Ι ¦ Ρ Ȝ ά ϋ Έ ܰ ೾ ! 3118 ා޺গςΑΠͅ۾̳࣭ͥषܖ੔!

2007 ා 1 ࠮ 1 ඾อ࢘ 2007 ᐕ 1 ᦬⊒ⴕ

  

઒⸶

   

਎⇇ࠕࡦ࠴࡮࠼࡯ࡇࡦࠣⷙ⒟

㩿㪫㪿㪼㩷㪮㫆㫉㫃㪻㩷㪘㫅㫋㫀㪄㪛㫆㫇㫀㫅㪾㩷㪚㫆㪻㪼㪀㩷

 

 ᐕ⑌ᱛ࡝ࠬ࠻࿖㓙ၮḰ

(The 2007 Prohibited List International Standard)





         

 ᐕ  ᦬  ᣣߦ⊒ലߔࠆ

THE 2007 PROHIBITED LIST

WORLD ANTI-DOPING CODE

Valid 1 January 2007

The use of any drug should be limited to medically justified indications

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES

(IN-AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES

S1. ANABOLIC AGENTS

Anabolic agents are prohibited.

1. Anabolic Androgenic Steroids (AAS) a. Exogenous* _{AAS, including:}

1-androstendiol (5α-androst-1-ene-3β,17β-diol); 1-androstendione (5α-androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole);

dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol);

drostanolone;

ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol;

ᐕ⑌ᱛ࡝ࠬ࠻࿖㓙ၮḰ

㧔ᣣᧄ૕⢒දળ࠼࡯ࡇࡦࠣ࠺࡯࠲ࡌ࡯ࠬ૞ᚑ⃰઒⸶㧕

ᐕ᦬ᣣ⊒ല

 ޿߆ߥࠆ⮎‛߽ޔකቇ⊛ߦᱜᒰߥㆡᔕߦ㒢ߞߡ૶↪ߐࠇߥߌࠇ߫ߥࠄߥ޿ޕ

Σ㧚Ᏹߦ⑌ᱛߐࠇࠆ‛⾰ߣᣇᴺ㧔┹ᛛળᬌᩏ෸߮┹ᛛᄖᬌᩏ㧕

ࢲએ࿜૏

S1 Ⱞ⊕หൻ⮎

Ⱞ⊕หൻ⮎ߪ⑌ᱛߐࠇࠆޕ

1. Ⱞ⊕หൻ↵ᕈൻ䉴䊁䊨䉟䊄⮎ (AAS)

a. ᄖ࿃ᕈ*_{AAS㧧଀ߣߒߡਅ⸥ߩ߽ߩ߇޽ࠆޕ} 1-ǢȳȉȭǹȆȳǸǪȸȫ㧔5ǩ-ࠕࡦ࠼ࡠࠬ࠻-1-ࠛࡦ-3Ǫ, 17Ǫ-ࠫࠝ࡯࡞㧕㧧 1-ǢȳȉȭǹȆȳǸǪȳ㧔5ǩ-ࠕࡦ࠼ࡠࠬ࠻-1-ࠛࡦ-3, 17-ࠫࠝࡦ㧕㧧 ȜȩȳǸǪȸȫ㧔19-ࡁ࡞ࠕࡦ࠼ࡠࠬ࠹ࡦࠫࠝ࡯࡞㧕㧧 ȜȩǹȆȭȳ㧧 ȜȫȇȎȳ㧧 ȜȫǸǪȳ㧔ࠕࡦ࠼ࡠࠬ࠲-1, 4-ࠫࠛࡦ-3, 17-ࠫࠝࡦ㧕㧧 ǫȫǹȆȭȳ㧧 ǯȭǹȆȜȸȫ㧧 ȀȊǾȸȫ㧔17ǩ-ࠛ࠴࠾࡞-17Ǫ-ࡅ࠼ࡠࠠࠪࠕࡦ࠼ࡠࠬ࠻-4-ࠛࡁ[2, 3-d]ࠗ࠰ࠠࠨ࠱࡯࡞㧕㧧 ȇȒȉȭǯȭȭȡȁȫȆǹȈǹȆȭȳ㧔4-ࠢࡠࡠ-17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠕࡦ࠼ࡠࠬ࠲-1, 4-ࠫࠛࡦ-3-ࠝࡦ㧕㧧 ȇǽǭǷȡȁȫȆǹȈǹȆȭȳ㧔17ǩ-ࡔ࠴࡞-5ǩ-ࠕࡦ࠼ࡠࠬ࠻-2-ࠛࡦ-17Ǫ-ࠝ࡯࡞㧕㧧 ȉȭǹǿȎȭȳ㧧 ǨȁȫǨǹȈȬȎȸȫ㧔19-ࡁ࡞-17ǩ-ࡊ࡟ࠣࡦ-4-ࠛࡦ-17-ࠝ࡯࡞㧕㧧 ȕȫǪǭǷȡǹȆȭȳ㧧 ȕǩȫȡȜȭȳ㧧 ȕȩǶȜȸȫ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞-5ǩ-ࠕࡦ࠼ࡠࠬ࠲ࡁ [2, 3-㨏]-ࡈ࡜ࠩࡦ㧕㧧 DzǹȈȪȎȳ㧧 4-ȒȉȭǭǷȆǹȈǹȆȭȳ㧔4, 17Ǫ-ࠫࡅ࠼ࡠࠠࠪࠕࡦ࠼ࡠࠬ࠻-㧠-ࠛࡦ-3-ࠝࡦ㧕㧧 ȡǹǿȎȭȳ㧧 ȡǹȆȭȭȳ㧧 ȡȆȎȭȳ㧧 ȡǿȳǸǨȎȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠕࡦ࠼ࡠࠬ࠲-1, 4-ࠫࠛࡦ-3-ࠝࡦ㧕㧧 ȡǿȳȉȪǪȸȫ㧧

methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltrienolone (17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); methyltestosterone; mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone;

prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol); quinbolone;

stanozolol; stenbolone;

1-testosterone (17β-hydroxy-5α-androst-1-en-3-one);

tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone and other substances with a similar chemical structure or similar biological effect(s).

b. Endogenous** _AAS:

androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene-3,17-dione);

dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); prasterone (dehydroepiandrosterone, DHEA);

testosterone and the following metabolites and isomers: 5α-androstane-3α,17α-diol; 5_{α-androstane-3α,17β-diol;} 5α-androstane-3β,17α-diol; 5_{α-androstane-3β,17β-diol;} androst-4-ene-3α,17α-diol; androst-4-ene-3_{α,17β-diol;} androst-4-ene-3β,17α-diol; androst-5-ene-3_{α,17α-diol;} androst-5-ene-3α,17β-diol; androst-5-ene-3_{β,17α-diol;}

ȡǿǹȆȭȳ㧔2ǩ,17ǩ-ࠫࡔ࠴࡞-5ǩ-ࠕࡦ࠼ࡠࠬ࠲ࡦ-3-ࠝࡦ-17Ǫ-ࠝ࡯࡞㧕㧧 ȡȁȫǸǨȎȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠛࠬ࠻࡜-4, 9-ࠫࠛࡦ-3-ࠝࡦ㧕㧧 ȡȁȫ-1-ȆǹȈǹȆȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞-5ǩ-ࠕࡦ࠼ࡠࠬ࠻-1-ࠛࡦ-3-ࠝࡦ㧕㧧 ȡȁȫȎȫȆǹȈǹȆȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠛࠬ࠻࡞-4-ࠛࡦ-3-ࠝࡦ㧕㧧 ȡȁȫȈȪǨȎȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠛࠬ࠻࡜-4, 9, 11-࠻࡝ࠛࡦ-3-ࠝࡦ㧕㧧 ȡȁȫȆǹȈǹȆȭȳ㧧 ȟȜȬȭȳ㧧 Ȋȳȉȭȭȳ㧧 19-ȎȫǢȳȉȭǹȆȳǸǪȳ㧔ࠛࠬ࠻࡞-㧠-ࠛࡦ 3, 17-ࠫࠝࡦ㧕㧧 ȎȫȜȬȈȳ㧧 ȎȫǯȭǹȆȜȸȫ㧧 ȎȫǨǿȳȉȭȭȳ㧧 ǪǭǵȜȭȳ㧧 Ǫǭǵȳȉȭȭȳ㧧 ǪǭǷȡǹȆȭȳ㧧 ǪǭǷȡȈȭȳ㧧 ȗȭǹǿȎǾȸȫ㧔[3, 2-㨏]ࡇ࡜࠱࡯࡞-5ǩ-ࠛ࠴ࠝࠕࡠࠦ࡜ࡦ-17Ǫ-࠹࠻࡜ࡅ࠼ࡠࡇ࡜ࡁ࡯࡞㧕㧧 ǭȳȜȭȳ㧧 ǹǿȎǾȭȸȫ㧧 ǹȆȳȜȭȳ㧧 1-ȆǹȈǹȆȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-5ǩ-ࠕࡦ࠼ࡠࠬ࠻-1-ࠛࡦ-3-ࠝࡦ㧕㧧 ȆȈȩȒȉȭDzǹȈȪȎȳ㧔18ǩ-ࡎࡕ-ࡊ࡟ࠣ࠽-4, 9, 11-࠻࡝ࠛࡦ-17Ǫ-ࠝ࡯࡞-3-ࠝࡦ㧕㧧 ȈȬȳȜȭȳ෸߮㘃ૃߩൻቇ᭴ㅧ෶ߪ㘃ૃߩ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆ߽ߩޕ b. ౝ࿃ᕈ**_AAS㧦 ǢȳȉȭǹȆȳǸǪȸȫ㧔ࠕࡦ࠼ࡠࠬ࠻-5-ࠛࡦ-3Ǫ, 17Ǫ-ࠫࠝ࡯࡞㧕㧧 ǢȳȉȭǹȆȳǸǪȳ㧔ࠕࡦ࠼ࡠࠬ࠻-4-ࠛࡦ-3, 17-ࠫࠝࡦ㧕㧧 ǸȒȉȭȆǹȈǹȆȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-5ǩ-ࠕࡦ࠼ࡠࠬ࠲ࡦ-3-ࠝࡦ㧕㧧 ȗȩǹȆȭȳ㧔࠺ࡅ࠼ࡠࠛࡇࠕࡦ࠼ࡠࠬ࠹ࡠࡦޔDHEA)㧧 ȆǹȈǹȆȭȳ෸߮ਅ⸥ߩઍ⻢‛ߣ⇣ᕈ૕ 5-Ǣȳȉȭǹǿȳ-3, 17-ǸǪȸȫᲵ 5-Ǣȳȉȭǹǿȳ-3, 17‚-ǸǪȸȫᲵ 5-Ǣȳȉȭǹǿȳ-3‚, 17-ǸǪȸȫᲵ 5-Ǣȳȉȭǹǿȳ-3‚, 17‚-ǸǪȸȫᲵ ǢȳȉȭǹȈ-4-Ǩȳ-3, 17-ǸǪȸȫᲵ ǢȳȉȭǹȈ-4-Ǩȳ-3, 17‚-ǸǪȸȫᲵ ǢȳȉȭǹȈ-4-Ǩȳ-3‚, 17-ǸǪȸȫᲵ ǢȳȉȭǹȈ-5-Ǩȳ-3, 17-ǸǪȸȫᲵ ǢȳȉȭǹȈ-5-Ǩȳ-3, 17‚-ǸǪȸȫᲵ

4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5-ene-3,17-dione); epi-dihydrotestosterone; 3α-hydroxy-5α-androstan-17-one; 3_{β-hydroxy-5α-androstan-17-one;} 19-norandrosterone; 19-noretiocholanolone.

Where an anabolic androgenic steroid is capable of being produced endogenously, a Sample will be deemed to contain such Prohibited Substance where the concentration of such Prohibited Substance or its metabolites or markers and/or any other relevant ratio(s) in the Athlete’s Sample so deviates from the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. A Sample shall not be deemed to contain a Prohibited

Substance in any such case where an Athlete proves that the concentration of the Prohibited Substance or its metabolites or markers and/or the relevant ratio(s) in

the Athlete’s Sample is attributable to a physiological or pathological condition. In all cases, and at any concentration, the Athlete’s sample will be deemed to contain a Prohibited Substance and the laboratory will report an Adverse

Analytical Finding if, based on any reliable analytical method (e.g. IRMS), the

laboratory can show that the Prohibited Substance is of exogenous origin. In such case, no further investigation is necessary.

If a value in the range of levels normally found in humans is reported and the reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, but if there are indications, such as a comparison to endogenous reference steroid profiles, of a possible Use of a Prohibited Substance, further investigation shall be conducted by the relevant Anti-Doping Organization by reviewing the results of any previous test(s) or by conducting subsequent test(s), in order to determine whether the result is due to a physiological or pathological condition, or has occurred as a consequence of the exogenous origin of a

Prohibited Substance.

When a laboratory has reported a T/E ratio greater than four (4) to one (1) and any reliable analytical method (e.g. IRMS) applied has not determined the exogenous origin of the substance, further investigation may be conducted by a review of previous tests or by conducting subsequent test(s), in order to determine whether the result is due to a physiological or pathological condition, or has occurred as a consequence of the exogenous origin of a Prohibited Substance. If a laboratory reports, using an additional reliable analytical method (e.g. IRMS), that the Prohibited Substance is of exogenous origin, no further investigation is necessary and the Sample will be deemed to contain such Prohibited Substance. When an additional reliable analytical method (e.g. IRMS) has not been applied and a minimum of three previous test results are not available, a longitudinal profile of the Athlete shall be established by performing a minimum of three no advance notice tests in a period of three months by the relevant Anti-Doping

Organization. If the longitudinal profile of the Athlete established by the

subsequent tests is not physiologically normal, the result shall be reported as an

4-ǢȳȉȭǹȆȳǸǪȸȫ㧔ࠕࡦ࠼ࡠࠬ࠻-4-ࠛࡦ-3Ǫ, 17Ǫ-ࠫࠝ࡯࡞㧕㧧 5-ǢȳȉȭǹȆȳǸǪȳ㧔ࠕࡦ࠼ࡠࠬ࠻-5-ࠛࡦ-3, 17-ࠫࠝࡦ㧕㧧 ǨȔ-ǸȒȉȭȆǹȈǹȆȭȳ㧧 3-ȒȉȭǭǷ-5-Ǣȳȉȭǹǿȳ-17-Ǫȳ㧧 3‚-ȒȉȭǭǷ-5-Ǣȳȉȭǹǿȳ-17-Ǫȳ㧧 19-ȎȫǢȳȉȭǹȆȭȳ㧧 19-ȎȫǨȁǪdzȩȎȭȳޕ ਄⸥ߩࠃ߁ߥ૕ౝߢ⥄ὼߦߟߊࠄࠇࠆⰮ⊕หൻ↵ᕈൻࠬ࠹ࡠࠗ࠼⮎ߦߟ޿ߡߪޔᬌ૕ਛߩ⑌ᱛ‛⾰ޔߘ ߩઍ⻢‛෶ߪࡑ࡯ࠞ࡯ߩỚᐲ߅ࠃ߮㧛߹ߚߪߘߩઁ㑐ㅪ‛⾰ߣߩᲧ₸߇ᱜᏱ▸࿐߆ࠄ߆ߌ㔌ࠇޔᱜᏱߦౝ ࿃ᕈߦ↥↢ߐࠇߚ‛⾰ߣߪ್ᢿߢ߈ߥ޿႐วޔᬌ૕ߦߪ⑌ᱛ‛⾰߇฽߹ࠇߡ޿ࠆߣߺߥߐࠇࠆޕߚߛߒޔ ⑌ᱛ‛⾰ޔߘߩઍ⻢‛෶ߪࡑ࡯ࠞ࡯ߩỚᐲ߅ࠃ߮㧛߹ߚߪߘߩઁ㑐ㅪ‛⾰ߣߩᲧ₸߇↢ℂ⊛޽ࠆ޿ߪ∛⊛ ⁁ᘒߦ⿠࿃ߔࠆߎߣࠍ┹ᛛ⠪߇┙⸽ߒߚ႐วޔᬌ૕ߦ⑌ᱛ‛⾰߇฽߹ࠇߡ޿ࠆߣߪߺߥߐࠇߥ޿ޕ ޿߆ߥࠆ႐วߦ߅޿ߡ߽ޔ߹ߚޔ޿߆ߥࠆỚᐲߢ޽ߞߡ߽ା㗬ᕈߩ㜞޿ಽᨆᣇᴺ(IRMS*╬)ߦၮߠ޿ ߡಽᨆᯏ㑐߇ߘߩ⑌ᱛ‛⾰߇ᄖ࿃ᕈ↱᧪ߢ޽ࠆߎߣࠍ⸽᣿ߢ߈ࠆ႐วߦߪޔᬌ૕ߦ⑌ᱛ‛⾰߇฽߹ࠇߡ ޿ࠆߣߺߥߐࠇࠆߩߢޔಽᨆᯏ㑐ߪ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߔࠆߎߣߦߥࠆޕߘߩࠃ߁ߥ႐ วߦߪㅊട⺞ᩏߪᔅⷐߣߐࠇߥ޿ޕ *_{IRMS㧦ห૏૕Ყ⾰㊂ಽᨆᴺ} ᬌᩏ୯߇ᱜᏱ▸࿐ౝߢ޽ࠅޔା㗬ߢ߈ࠆಽᨆᣇᴺ(IRMS ╬)ߢᄖ࿃ᕈߢ޽ࠆߎߣ߇᳿ቯߢ߈ߥ޿႐วߢ ߽ޔෳᾖߔߴ߈ࠬ࠹ࡠࠗ࠼ࡊࡠࡈࠔࠗ࡞ߣᲧセߒߡޔ⑌ᱛ‛⾰ࠍ૶↪ߒߚน⢻ᕈ߇޽ࠆߣ޿߁ళ୥߇޽ ࠆߣ್ᢿߐࠇࠆ႐วޔ㑐ㅪࠕࡦ࠴࡮࠼࡯ࡇࡦࠣᯏ㑐ߪޔߘߩ⚿ᨐ߇↢ℂ⊛޽ࠆ޿ߪ∛⊛⁁ᘒߦ⿠࿃ߔࠆ ߆ޔ߹ߚߪᄖ࿃ᕈߩⰮ⊕หൻ↵ᕈൻࠬ࠹ࡠࠗ࠼⮎ߦ⿠࿃ߔࠆ߆ࠍ್ᢿߔࠆὑߦޔㆊ෰ߩ⚿ᨐࠍᬌ⸛ߔࠆޔ ޽ࠆ޿ߪㅊ〔ᬌᩏࠍⴕ߁ޕ ಽᨆᯏ㑐߆ࠄޔዩਛߩ T/E Ყ߇ 4 ࠍ⿥߃ߡႎ๔ߐࠇޔା㗬ߢ߈ࠆಽᨆᣇᴺ(IRMS ╬)ߦࠃߞߡ߽ᄖ࿃ ᕈߩ⑌ᱛ‛⾰ߢ޽ࠆߣ್ᢿߢ߈ߥ޿႐วޔߘߩᲧ₸߇↢ℂ⊛࡮∛⊛⁁ᘒߦ⿠࿃ߔࠆ߆޽ࠆ޿ߪᄖ࿃ᕈߩ Ⱞ⊕หൻ↵ᕈൻࠬ࠹ࡠࠗ࠼⮎↱᧪ߢ޽ࠆ߆ุ߆ࠍ್ᢿߔࠆߚ߼ޔㆊ෰ߩ⚿ᨐࠍᬌ⸛ߔࠆޔ޽ࠆ޿ߪㅊ〔 ᬌᩏߦࠃࠅߐࠄߦ⺞ᩏߔࠆߎߣ߇ߢ߈ࠆޕಽᨆᯏ㑐߆ࠄႎ๔ߐࠇߚ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐ߇ޔା㗬ߩ߅ ߌࠆಽᨆᣇᴺ(IRMS ╬)ࠍ↪޿ߡᄖ࿃ᕈߩⰮ⊕หൻ↵ᕈൻࠬ࠹ࡠࠗ࠼⮎ߢ޽ࠆߎߣࠍ⸽᣿ߒߡ޿ࠆ႐ว ߦߪޔㅊട⺞ᩏߪᔅⷐߣߐࠇߕޔᬌ૕ߦ⑌ᱛ‛⾰߇฽߹ࠇߡ޿ࠆߣߺߥߐࠇࠆޕା㗬ᕈߩ޽ࠆಽᨆᣇᴺ (IRMS ╬)߇ㅊട⊛ߦⴕࠊࠇߕޔ߆ߟᦨૐㆊ෰ 3 ࿁ߩ⚿ᨐ߇೑↪ߢ߈ߥ޿႐วޔ㑐ㅪࠕࡦ࠴࡮࠼࡯ࡇࡦࠣ ᯏ㑐ߪ3 ࡩ᦬એౝߦዋߥߊߣ߽ 3 ࿁ߩ੍๔ήߒᬌᩏࠍታᣉߔࠆߎߣߦࠃߞߡᒰ⹥┹ᛛ⠪ߩ㐳ᦼ⊛ࡊࡠࡈ ࠔࠗ࡞ࠍ᣿ࠄ߆ߦߒߥߌࠇ߫ߥࠄߥ޿ޕߎࠇࠄㅊ〔ᬌᩏߦࠃߞߡ᣿ࠄ߆ߦߐࠇߚ┹ᛛ⠪ߩ㐳ᦼ⊛ࠬ࠹ࡠ ࠗ࠼ࡊࡠࡈࠔࠗ࡞߇↢ℂ⊛ߦᱜᏱߢߪߥ޿႐วޔ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߐࠇߥߌࠇ߫ߥࠄ ߥ޿ޕ

In extremely rare individual cases, boldenone of endogenous origin can be consistently found at very low nanograms per milliliter (ng/mL) levels in urine. When such a very low concentration of boldenone is reported by a laboratory and the application of any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation may be conducted by subsequent tests. When an additional reliable analytical method (e.g. IRMS) has not been applied, a longitudinal profile of the athlete shall be established by performing a minimum of three no advance notice tests in a period of three months by the relevant Anti-Doping Organization. If the longitudinal profile of the

Athlete established by the subsequent tests is not physiologically normal, the

result shall be reported as an Adverse Analytical Finding.

For 19-norandrosterone, an Adverse Analytical Finding reported by a laboratory is considered to be scientific and valid proof of exogenous origin of the Prohibited

Substance. In such case, no further investigation is necessary.

Should an Athlete fail to cooperate in the investigations, the Athlete’s Sample shall be deemed to contain a Prohibited Substance.

㕖Ᏹߦ⒘ߛ߇ޔ୘ੱߦࠃߞߡߪޔౝ࿃ᕈߩࡏ࡞࠺ࡁࡦ߇࠽ࡁࠣ࡜ࡓ㧛ࡒ࡝࡝࠶࠻࡞㧔ng/mL㧕ߩ࡟ࡌ ࡞ߢ㕖ᏱߦૐỚᐲߢߪ޽ࠆ߇ዩਛߦᏱᤨᬌ಴ߐࠇࠆߎߣ߇޽ࠆޕߘߩࠃ߁ߥߏߊૐỚᐲߩࡏ࡞࠺ࡁࡦࠍ ಽᨆᯏ㑐߇ႎ๔ߒޔା㗬ߩ߅ߌࠆಽᨆᣇᴺ(IRMS ╬)ߩㆡ↪ߦࠃߞߡ߽ࡏ࡞࠺ࡁࡦ߇ᄖ࿃ᕈ↱᧪ߢ޽ࠆߣ ್ᢿߐࠇߥ޿႐วޔㅊ〔ᬌᩏߦࠃࠅߐࠄߦ⺞ᩏߔࠆߎߣ߇ߢ߈ࠆޕା㗬ᕈߩ޽ࠆಽᨆᣇᴺ(IRMS ╬)߇ㅊട ⊛ߦⴕࠊࠇߥ޿႐วޔ㑐ㅪࠕࡦ࠴࡮࠼࡯ࡇࡦࠣᯏ㑐ߪ3 ࡩ᦬એౝߦዋߥߊߣ߽ 3 ࿁ߩ੍๔ήߒᬌᩏࠍᒰ ⹥┹ᛛ⠪ߦኻߒታᣉߒߥߌࠇ߫ߥࠄߥ޿ޕ৻ㅪߩᬌᩏࠍฃߌߚ┹ᛛ⠪ߩ㐳ᦼ⊛ࠬ࠹ࡠࠗ࠼ࡊࡠࡈࠔࠗ࡞ ߇↢ℂ⊛ߦᱜᏱߢߪߥ޿႐วޔ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߐࠇߥߌࠇ߫ߥࠄߥ޿ޕ 19-ࡁ࡞ࠕࡦ࠼ࡠࠬ࠹ࡠࡦߦ㑐ߒߡߪޔಽᨆᯏ㑐ߦࠃߞߡႎ๔ߐࠇߚ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߪ⑌ᱛ ‛⾰߇ᄖ࿃ᕈ↱᧪ߢ޽ࠆߎߣߩ⑼ቇ⊛߆ߟ᦭ലߥ⸽᜚ߣ⠨߃ࠄࠇࠆޕߘߩࠃ߁ߥ႐วߦߪㅊട⺞ᩏߪᔅ ⷐߣߐࠇߥ޿ޕ ┹ᛛ⠪߇ߎߩ⺞ᩏ߳ߩදജࠍᕃߞߚ႐วޔᒰ⹥┹ᛛ⠪ߩᬌ૕ߦ⑌ᱛ‛⾰߇฽߹ࠇߡ޿ࠆߣ⷗ߥߐࠇࠆ ߎߣߦߥࠆޕ 

2. Other Anabolic Agents, including but not limited to: Clenbuterol, tibolone, zeranol, zilpaterol.

For purposes of this section:

* _{“exogenous” refers to a substance which is not ordinarily capable of being}

produced by the body naturally.

** _{“endogenous” refers to a substance which is capable of being produced by the}

body naturally.

S2. HORMONES AND RELATED SUBSTANCES

The following substances, including other substances with a similar chemical structure or similar biological effect(s), and their releasing factors, are prohibited:

1. Erythropoietin (EPO);

2. Growth Hormone (hGH), Insulin-like Growth Factors (e.g. IGF-1), Mechano Growth Factors (MGFs);

3. Gonadotrophins (LH, hCG), prohibited in males only; 4. Insulin;

5. Corticotrophins.

Unless the Athlete can demonstrate that the concentration was due to a physiological or pathological condition, a Sample will be deemed to contain a

Prohibited Substance (as listed above) where the concentration of the Prohibited Substance or its metabolites and/or relevant ratios or markers in the Athlete’s Sample so exceeds the range of values normally found in humans that it is

unlikely to be consistent with normal endogenous production.

If a laboratory reports, using a reliable analytical method, that the Prohibited

Substance is of exogenous origin, the Sample will be deemed to contain a Prohibited Substance and shall be reported as an Adverse Analytical Finding.

The presence of other substances with a similar chemical structure or similar biological effect(s), diagnostic marker(s) or releasing factors of a hormone listed above or of any other finding which indicate(s) that the substance detected is of exogenous origin, will be deemed to reflect the use of a Prohibited Substance and shall be reported as an Adverse Analytical Finding.

S3. BETA-2 AGONISTS

All beta-2 agonists including their D- and L-isomers are prohibited.

As an exception, formoterol, salbutamol, salmeterol and terbutaline when administered by inhalation, require an abbreviated Therapeutic Use Exemption. Despite the granting of any form of Therapeutic Use Exemption, a concentration of salbutamol (free plus glucuronide) greater than 1000 ng/mL will be considered an Adverse Analytical Finding unless the Athlete proves that the abnormal result was the consequence of the therapeutic use of inhaled salbutamol.

2. 䈠䈱ઁ䈱Ⱞ⊕หൻ⮎䋻଀䈫䈚䈩ਅ⸥䈱䉅䈱䈏䈅䉎

 ǯȬȳȖȆȭȸȫŴȁȜȭȳŴǼȩȎᲧȫŴǸȫȑȆȭȸȫ ߎߩ࠮࡚ࠢࠪࡦߦ߅޿ߡޔ **_{ޟᄖ࿃ᕈ(exogenous)ޠߣߪޔㅢᏱߪ૕ౝߢ⥄ὼߦߟߊࠄࠇᓧߥ޿‛⾰ࠍ޿߁ޕ} **_{ޟౝ࿃ᕈ(endogenous)ޠߣߪޔ૕ౝߢ⥄ὼߦߟߊࠄࠇᓧࠆ‛⾰ࠍ޿߁ޕ}

S2. 䊖䊦䊝䊮䈫㑐ㅪ‛⾰

ਅ⸥ߩ‛⾰ߪޔ㘃ૃߩൻቇ᭴ㅧ෶ߪ㘃ૃ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆߘߩઁߩ‛⾰෸߮ߘࠇࠄߩ᡼಴࿃ሶ߽ ฽߼ޔ⑌ᱛߐࠇࠆޕ  1. ǨȪǹȭȝǨȁȳᲢEPOᲣᲵ  2. ঺ᧈțȫȢȳᲢhGHᲣŴǤȳǹȪȳಮ঺ᧈ׆܇ᲢIGF-1 ╬ᲣŴೞ఺ႎ঺ᧈ׆܇ᲢMGFsᲣᲵ  3. ǴȊȉȈȭȔȳ᫏ᲢLH, hCGᲣŴ↵ᕈߦ߅޿ߡߩߺ⑌ᱛᲵ  4. ǤȳǹȪȳᲵ  5. dzȫȁdzȈȭȔȳ᫏Ჵ ᬌ૕ਛߩ⑌ᱛ‛⾰෶ߪߘߩઍ⻢‛ߩỚᐲ߅ࠃ߮㧛߹ߚߪ㑐ㅪߩᲧ₸߿ࡑ࡯ࠞ࡯߇ࡅ࠻ߩᱜᏱ▸࿐ࠍ ㅺ⣕ߒᱜᏱߦౝ࿃ᕈߦ↥↢ߐࠇߚ‛⾰ߣߺߥߐࠇߥ޿႐วޔ┹ᛛ⠪߇ߘߩỚᐲ߇↢ℂ⊛⁁ᘒ޽ࠆ޿ߪ∛ ⊛⁁ᘒߦ⿠࿃ߔࠆߎߣࠍ⸽᣿ߒߥ޿㒢ࠅޔߘߩ┹ᛛ⠪ߩᬌ૕ਛߦ⑌ᱛ‛⾰㧔਄⸥೉᜼㧕߇฽߹ࠇߡ޿ࠆ ߣߺߥߐࠇࠆޕ ಽᨆᯏ㑐߇ା㗬ߩ߅ߌࠆಽᨆᣇᴺߦࠃߞߡ⑌ᱛ‛⾰߇ᄖ࿃ᕈߢ޽ࠆߣႎ๔ߒߚ႐วޔᬌ૕ߪ⑌ᱛ‛⾰ ࠍ฽ࠎߢ޿ࠆߣߺߥߐࠇޔ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߐࠇࠆޕ ᬌ૕ਛߦ㘃ૃߩൻቇ᭴ㅧ߿↢‛ቇ⊛ലᨐࠍᜬߟઁߩ‛⾰ޔ⸻ᢿࡑ࡯ࠞ࡯㘃ޔ਄⸥ߦ೉᜼ߒߚࡎ࡞ࡕࡦ ߩ᡼಴࿃ሶ߇ᬌ಴ߐࠇߚ႐วޔ޽ࠆ޿ߪᬌ಴‛⾰߇૕ᄖ↱᧪ߢ޽ࠆߎߣ߇᣿ࠄ߆ߦߐࠇߚ႐วޔ⑌ᱛ‛ ⾰ߩ૶↪ࠍ෻ᤋߔࠆ߽ߩߣߺߥߒ㧘ߘࠇࠄߪ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߐࠇࠆޕ

S3 䊔䊷䉺 2 ૞↪⮎

ߔߴߡߩࡌ࡯࠲2 ૞↪⮎ߪޔߘߩ D ૕෸߮ L ૕߽฽߼ߡ⑌ᱛߐࠇࠆޕ ଀ᄖߣߒߡޔࡈࠜ࡞ࡕ࠹ࡠ࡯࡞ޔࠨ࡞ࡉ࠲ࡕ࡯࡞ޔࠨ࡞ࡔ࠹ࡠ࡯࡞ޔ࠹࡞ࡉ࠲࡝ࡦ߇ๆ౉૶↪ߐࠇࠆ ႐วߦߪޔ⇛ᑼߩᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎ߩ↳⺧߇ᔅⷐߣߥࠆޕ ޿߆ߥࠆᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎߇⹺߼ࠄࠇߡ޿ߡ߽ޔࠨ࡞ࡉ࠲ࡕ࡯࡞ߩỚᐲ(ࡈ࡝࡯ߣࠣ࡞ࠢࡠࡦ㉄ ᛴว૕ߩỚᐲ)߇ 1000 ng / ml એ਄ߩ႐วޔߘߩ⇣Ᏹ୯߇ࠨ࡞ࡉ࠲ࡕ࡯࡞ๆ౉ߦࠃࠆᴦ≮⋡⊛ߩ⚿ᨐߢ ޽ࠆߎߣࠍ┹ᛛ⠪߇┙⸽ߒߥ޿߆߉ࠅޔ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡᛒࠊࠇࠆߎߣߦߥࠆޕ

S4. AGENTS WITH ANTI-ESTROGENIC ACTIVITY

The following classes of anti-estrogenic substances are prohibited:

1. Aromatase inhibitors including, but not limited to, anastrozole,

letrozole, aminoglutethimide, exemestane, formestane, testolactone. 2. Selective Estrogen Receptor Modulators (SERMs) including, but not limited to, raloxifene, tamoxifen, toremifene.

3. Other anti-estrogenic substances including, but not limited to, clomiphene, cyclofenil, fulvestrant.

S5. DIURETICS AND OTHER MASKING AGENTS

Masking agents are prohibited. They include: Diuretics*_,

epitestosterone, probenecid,

alpha-reductase inhibitors (e.g. finasteride, dutasteride),

plasma expanders (e.g. albumin, dextran, hydroxyethyl starch) and other substances with similar biological effect(s).

Diuretics include: acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone,

thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except for drosperinone, which is not prohibited).

* _{A Therapeutic Use Exemption is not valid if an Athlete’s urine contains a diuretic}

S4. ᛫䉣䉴䊃䊨䉭䊮૞↪䉕᦭䈜䉎⮎‛

ਅ⸥ߩ᛫ࠛࠬ࠻ࡠࠥࡦ૞↪ࠍ᦭ߔࠆ‛⾰ߪ⑌ᱛߐࠇࠆޕ 1ᲨǢȭȞǿȸǼ᧹ܹᕤƱƠƯƸŴഏƷNjƷƕਫƛǒǕǔƕŴƜǕǒƴᨂܭƢǔNjƷưƸƳƍŵ ǢȊǹȈȭǾȸȫŴȬȈȭǾȸȫŴǢȟȎǰȫȆȁȟȉŴǨǯǹȡǹǿȳŴ ȕǩȫȡǹǿȳŴȆǹȈȩǯȈȳŵ 2Შᢠ৸ႎǨǹȈȭDzȳӖܾ˳ᛦራᕤᲢSERMsᲣƱƠƯƸŴഏƷNjƷƕਫƛǒǕǔƕŴƜǕǒƴᨂܭ ƢǔNjƷưƸƳƍŵ ȩȭǭǷȕǧȳŴǿȢǭǷȕǧȳŴȈȬȟȕǧȳ 3ᲨƦƷ˂Ʒ৴ǨǹȈȭDzȳ˺ဇǛஊƢǔᕤཋƱƠƯƸŴഏƷNjƷƕਫƛǒǕǔƕŴƜǕǒƴᨂܭƢ ǔNjƷưƸƳƍŵ ǯȭȟȕǧȳŴǷǯȭȕǧȋȫŴȕȫșǹȈȩȳȈŵ

S5. ೑ዩ⮎䈫ઁ䈱㓝⭁⮎

㓝⭁⮎ߪ⑌ᱛߐࠇࠆޕ㓝⭁⮎ߦߪਅ⸥ߩ߽ߩ߇฽߹ࠇࠆޕ Мބᕤ*Ŵ ǨȔȆǹȈǹȆȭȳŴ ȗȭșȍǷȉŴ -ᢩΨᣞእ᧹ܹᕤᲢȕǣȊǹȆȪȉŴȇȥǿǹȆȪȉ╬ᲣŴ ᘉ๶ف᣽ཋឋᲢǢȫȖȟȳŴȇǭǹȈȩȳŴȒȉȭǭǷǨȁȫȇȳȗȳ╬Უ ෸߮㘃ૃߩ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆ߽ߩޕ ೑ዩ⮎ߦߪޔਅ⸥ߩ߽ߩ߇฽߹ࠇࠆ㧧 ǢǻǿǾȩȟȉŴ ǢȟȭȪȉŴ ȖȡǿȋȉŴ ǫȳȬȎȳŴ ǯȭȫǿȪȉȳŴ ǨǿǯȪȳᣠŴ ȕȭǻȟȉŴ ǤȳȀȑȟȉŴ ȡȈȩǾȳŴ ǹȔȭȎȩǯȈȳŴ ȁǢǸȉ᫏ᲢșȳȉȭȕȫȡȁǢǸȉŴǯȭȭȁǢǸȉŴȒȉȭǯȭȭȁǢǸȉ╬ᲣŴ ȈȪǢȠȆȬȳŴ෸߮㘃ૃߩൻቇ᭴ㅧ෶ߪ㘃ૃߩ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆ߽ߩޕ 㧔ૉߒޔ࠼ࡠࠬࡍ࡝ࡁࡦߪ⑌ᱛ‛⾰ߦߪ฽߹ࠇߥ޿㧕 *_{┹ᛛ⠪ߩዩਛߦ޽ࠆ⑌ᱛ‛⾰߇㑣୯᳓Ḱ޽ࠆ޿ߪ㑣୯᳓Ḱᧂḩߢሽ࿷ߒޔ߆ߟ೑ዩ⮎߇฽߹ࠇߡ޿} ߚᤨޔᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎ߪήലߣߥࠆޕ

PROHIBITED METHODS

M1. ENHANCEMENT OF OXYGEN TRANSFER

The following are prohibited:

1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin.

2. Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products).

M2. CHEMICAL AND PHYSICAL MANIPULATION

1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Controls is prohibited. These include but are not limited to catheterisation, urine substitution and/or alteration.

2. Intravenous infusions are prohibited, except as a legitimate medical treatment.

M3. GENE DOPING

The non-therapeutic use of cells, genes, genetic elements, or of the modulation of gene expression, having the capacity to enhance athletic performance, is prohibited.

ࢲએုေ

M1. ㉄⚛ㆇ៝⢻䈱ᒝൻ

ਅ⸥ߩ੐㗄߇⑌ᱛߐࠇࠆޕ  1㧚ⴊᶧ࠼࡯ࡇࡦࠣޕⴊᶧ࠼࡯ࡇࡦࠣߣߪޔ⥄Ꮖⴊޔห⒳ⴊޔ⇣⒳ⴊ෶ߪߔߴߡߩ⿒ⴊ⃿⵾೷ࠍᛩਈ ߔࠆߎߣޕ  2㧚㉄⚛៨ข߿㉄⚛ㆇ៝㧘㉄⚛ଏ⛎ࠍੱὑ⊛ߦଦㅴߔࠆߎߣ㧔ㆊࡈ࡞ࠝࡠൻว‛ޔࠛࡈࠔࡊࡠࠠࠪ࡜ ࡯࡞(RSR13)ޔୃ㘼ࡋࡕࠣࡠࡆࡦ⵾೷㧔ࡋࡕࠣࡠࡆࡦࠍၮߦߒߚⴊᶧઍᦧ‛⾰ޔࡋࡕࠣࡠࡆࡦߩࡑ ࠗࠢࡠࠞࡊ࠮࡞⵾೷╬㧕߇฽߹ࠇࠆ߇ޔߎࠇࠄߦ㒢ቯߔࠆ߽ߩߢߪߥ޿㧕ޕ

M2. ൻቇ⊛䊶‛ℂ⊛ᠲ૞

 1㧚࠼࡯ࡇࡦࠣࠦࡦ࠻ࡠ࡯࡞ߢណขߐࠇߚᬌ૕ߩቢోᕈ෸߮᦭ലᕈࠍᄌൻߐߖࠆߚ߼ߦᡷߑࠎ෶ߪᡷ ߑࠎߒࠃ߁ߣߔࠆߎߣߪ⑌ᱛߐࠇࠆޕߎࠇࠄߦߪࠞ࠹࡯࠹࡞ߩ૶↪ޔዩߩߔࠅᦧ߃ޔዩߩᡷᄌߥ ߤ߇฽߹ࠇࠆ߇ޔߎࠇࠄߦ㒢ቯߔࠆ߽ߩߢߪߥ޿ޕ  2㧚ᱜᒰߥක≮ⴕὑࠍ㒰߈ޔ㕒⣂ౝᵈ౉ߪ⑌ᱛߐࠇࠆޕ

M3. ㆮવሶ䊄䊷䊏䊮䉫

ᴦ≮એᄖߩ⋡⊛ߢޔ┹ᛛ⢻ജࠍ㜞߼ࠆน⢻ᕈߩ޽ࠆ⚦⢩ޔㆮવሶޔㆮવ࿃ሶ෶ߪㆮવሶ⊒⃻ߩୃ㘼ߪ ⑌ᱛߐࠇࠆޕ

SUBSTANCES AND METHODS

PROHIBITED IN-COMPETITION

In addition to the categories S1 to S5 and M1 to M3 defined above,

the following categories are prohibited in competition:

PROHIBITED SUBSTANCES

S6. STIMULANTS

All stimulants (including both their (D- & L-) optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2007 Monitoring Program*_.

Stimulants include:

Adrafinil, adrenaline**_{, amfepramone, amiphenazole, amphetamine,}

amphetaminil,

benzphetamine, benzylpiperazine, bromantan,

cathine***_{, clobenzorex, cocaine, cropropamide, crotetamide,}

cyclazodone,

dimethylamphetamine,

ephedrine****_{, etamivan, etilamphetamine, etilefrine,}

famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, heptaminol,

isometheptene, levmethamfetamine,

meclofenoxate, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxyamphetamine, methylenedioxymethamphetamine, p-methylamphetamine, methylephedrine****_{, methylphenidate, modafinil,}

nikethamide, norfenefrine, norfenfluramine, octopamine, ortetamine, oxilofrine,

parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phenpromethamine, phentermine,

4-phenylpiracetam (carphedon), prolintane, propylhexedrine, selegiline, sibutramine, strychnine,

tuaminoheptane and other substances with a similar chemical structure or similar biological effect(s).

Τ㧚┹ᛛળᬌᩏߢ⑌ᱛኻ⽎ߣߥࠆ‛⾰࡮ᣇᴺ

 Э૨᳍Ძ᳸᳍ᲯŴ᳇Ძ᳸᳇ᲭƴьƑƯŴɦᚡƷǫȆǴȪȸƸᇤ২˟ƴƓƍƯᅠഥƞǕǔŵ

ࢲએ࿜૏

S6 ⥝ᅗ⮎

ߔߴߡߩ⥝ᅗ⮎㧔㑐ㅪߒߚߘߩశቇ⇣ᕈ૕㧔D ૕෸߮ L ૕㧕߽฽߼ߡ㧕ߪޔዪᚲ૶↪ߐࠇࠆࠗࡒ࠳࠱ ࡯࡞⺃ዉ૕ߣ2007 ᐕ⋙ⷞࡊࡠࠣ࡜ࡓ*ߦ฽߹ࠇࠆ⮎‛ࠍ㒰޿ߡޔ⑌ᱛߐࠇࠆޕ ǢȉȩȕǣȋȫŴǢȉȬȊȪȳ**ŴǢȳȕǧȗȩȢȳŴǢȟȕǧȊǾȸȫŴǢȳȕǧǿȟȳŴ ǢȳȕǧǿȟȋȫŴ șȳǺȕǧǿȟȳŴșȳǸȫȔȚȩǸȳŴȖȭȞȳǿȳŴ ǫȁȳ***ŴǯȭșȳǾȬȃǯǹŴdzǫǤȳŴǯȭȗȭȑȟȉŴǯȭȆǿȟȉŴ ǷǯȩǾȉȳŴ ǸȡȁȫǢȳȕǧǿȟȳŴ ǨȕǧȉȪȳ****ŴǨǿȟȐȳŴǨȁȫǢȳȕǧǿȟȳŴǨȁȬȕȪȳŴ ȕǡȳȗȭȕǡǾȳŴȕǧȳȖȈȩǼȸȈŴȕǧȳǫȳȕǡȟȳŴȕǧȳǫȟȳŴ ȕǧȍȁȪȳŴȕǧȳȕȫȩȟȳŴȕǧȳȗȭȝȬȃǯǹŴȕȫȕǧȎȬȃǯǹŴ ȘȗǿȟȎȸȫŴ ǤǽȡȆȗȆȳŴ ȬȖȡǿȳȕǧǿȟȳŴ ȡǯȭȕǧȎǭǻȸȈŴȡȕǧȎȬȃǯǹŴȡȕǧȳȆȫȟȳŴȡǽǫȫȖŴ ȡǿȳȕǧǿȟȳᲢD˳ᲣŴȡȁȬȳǸǪǭǷǢȳȕǧǿȟȳŴ ȡȁȬȳǸǪǭǷȡǿȳȕǧǿȟȳŴp-ȡȁȫǢȳȕǧǿȟȳŴ ȡȁȫǨȕǧȉȪȳ****ŴȡȁȫȕǧȋȇȸȈŴȢȀȕǣȋȫŴ ȋDZǿȟȉŴȎȫȕǧȍȕȪȳŴȎȫȕǧȳȕȫȩȟȳŴ ǪǯȈȑȟȳŴǪȫȆǿȟȳŴǪǭǷȭȕȪȳŴ ȑȩȒȉȭǭǷǢȳȕǧǿȟȳŴȚȢȪȳŴȚȳȆȈȩǾȸȫŴȕǧȳǸȡȈȩǸȳŴ ȕǧȳȡȈȩǸȳŴȕǧȳȗȭȡǿȟȳŴȕǧȳȆȫȟȳŴ 4-ȕǧȋȫȔȩǻǿȠᲢǫȫȕǧȉȳᲣŴȗȭȪȳǿȳŴȗȭȔȫȘǭǻȉȪȳŴ ǻȬǮȪȳŴǷȖȈȩȟȳŴǹȈȪǭȋȸȍŴ ȄǢȟȎȘȗȆȳ෸߮㘃ૃߩൻቇ᭴ㅧ෶ߪ㘃ૃߩ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆ߽ߩޕ

* _{The following substances included in the 2007 Monitoring Program (bupropion,}

caffeine, phenylephrine, phenylpropanolamine, pipradol, pseudoephedrine, synephrine) are not considered as Prohibited Substances.

** _{Adrenaline associated with local anaesthetic agents or by local administration}

(e.g. nasal, ophthalmologic) is not prohibited.

*** _{Cathine is prohibited when its concentration in urine is greater than 5}

micrograms per milliliter.

**** _{Each of ephedrine and methylephedrine is prohibited when its}

concentration in urine is greater than 10 micrograms per milliliter.

A stimulant not expressly mentioned as an example under this section should be considered as a Specified Substance only if the Athlete can establish that the substance is particularly susceptible to unintentional anti-doping rule violations because of its general availability in medicinal products or is less likely to be successfully abused as a doping agent.

S7. NARCOTICS

The following narcotics are prohibited:

buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.

S8. CANNABINOIDS

Cannabinoids (e.g. hashish, marijuana) are prohibited.

S9. GLUCOCORTICOSTEROIDS

All glucocorticosteroids are prohibited when administered orally, rectally, intravenously or intramuscularly. Their use requires a Therapeutic Use Exemption approval.

Other routes of administration (intraarticular /periarticular/ peritendinous/ epidural/ intradermal injections and inhalation) require an Abbreviated Therapeutic Use Exemption except as noted below.

Topical preparations when used for dermatological (including iontophoresis/phonophoresis), auricular, nasal, ophthalmic, buccal, gingival and perianal disorders are not prohibited and do not require any form of Therapeutic Use Exemption.

**** _{2007 ᐕ⋙ⷞࡊࡠࠣ࡜ࡓߦ฽߹ࠇࠆ‛⾰㧔ࡉࡊࡠࡇࠝࡦޔࠞࡈࠚࠗࡦޔࡈࠚ࠾࡟ࡈ࡝ࡦޔࡈࠚ࠾࡞ࡊ} ࡠࡄࡁ࡯࡞ࠕࡒࡦޔࡇࡊ࡜࠼࡯࡞ޔࡊ࠰ࠗ࠼ࠛࡈࠚ࠼࡝ࡦޔࠪࡀࡈ࡝ࡦ㧕ߪ⑌ᱛ‛⾰ߣߺߥߐߥ޿ޕ **** _{ࠕ࠼࡟࠽࡝ࡦߪޔዪᚲ㤗㈮⮎ߣߩ૬↪޽ࠆ޿ߪዪᚲ૶↪㧔㥦ޔ⌒╬㧕ߩ႐วޔ⑌ᱛߐࠇߥ޿ޕ} **** _{ǫȁȳ㧧ዩਛỚᐲ5Njg/ml એ਄߇⑌ᱛޕ} **** _{ǨȕǧȉȪȳߣȡȁȫǨȕǧȉȪȳ㧧ዩਛỚᐲ10 Njg/ml એ਄߇⑌ᱛޕ} ߎߩ࠮࡚ࠢࠪࡦߢ଀ߣߒߡ᣿⏕ߦ᜼ߍࠄࠇߡ޿ߥ޿⥝ᅗ⮎ߪޔ┹ᛛ⠪߇ߘߩ⮎‛߇ක⮎ຠߣߒߡᐢߊ Ꮢ⽼ߐࠇޔᓥߞߡਇᵈᗧߢ࠼࡯ࡇࡦࠣⷙೣ㆑෻ࠍ․ߦ⿠ߎߒ߿ߔ޿⮎‛ߢ޽ࠆޔ޽ࠆ޿ߪ࠼࡯ࡇࡦࠣ‛ ⾰ߣߒߡߪᲧセ⊛ੂ↪ߐࠇࠆߎߣ߇ዋߥ޿⮎‛ߢ޽ࠆߎߣࠍ⸽᣿ߒߚ႐วߩߺޔᜰቯ‛⾰ߣߒߡ⠨ᘦߐ ࠇࠆߴ߈ߢ޽ࠆޕ

S7 㤗⮎

ਅ⸥ߩ㤗⮎ߪ⑌ᱛߐࠇࠆޕ ȖȗȬȎȫȕǣȳŴȇǭǹȈȭȢȩȟȉŴǸǢȢȫȒȍᲢȘȭǤȳᲣŴȕǧȳǿȋȫӏƼᛔݰ˳Ŵ ȒȉȭȢȫȕǩȳŴȡǵȉȳŴȢȫȒȍŴǪǭǷdzȉȳŴǪǭǷȢȫȕǩȳŴ ȚȳǿǾǷȳŴȚȁǸȳŵ

S8 䉦䊮䊅䊎䊉䉟䊄

ࠞࡦ࠽ࡆࡁࠗ࠼㧔ࡂࠪࠪࡘޔࡑ࡝ࡈࠔ࠽╬㧕ߪ⑌ᱛߐࠇࠆޕ

S9 ♧⾰䉮䊦䉼䉮䉟䊄

♧⾰ࠦ࡞࠴ࠦࠗ࠼ߩ⚻ญ૶↪ޔ⚻⋥⣺૶↪ޔ㕒⣂ౝ૶↪ޔ╭⡺ౝ૶↪ߪߔߴߡ⑌ᱛߐࠇࠆޕߎࠇࠄߩ ૶↪ߦ޽ߚߞߡߪޔᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎ߩᛚ⹺߇ᔅⷐߣߥࠆޕ ߘߩઁߩ૶↪⚻〝㧔㑐▵ౝ㧛㑐▵๟࿐㧛⣷๟࿐㧛⎬⤑ᄖ㧛⊹ౝᵈ౉߅ࠃ߮ๆ౉㧕ߦߟ޿ߡߪޔਅ⸥ߩ႐ว ࠍ㒰߈ޔ⇛ᑼߩᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎߇ᔅⷐߣߥࠆޕ ⊹⤏㧔ࠗࠝࡦ࠻ࡈࠜ࡟ࠪࠬ㧛ࡈࠜࡁࡈࠜ࡟ࠪࠬࠍ฽߻㧕ޔ⡊ޔ㥦ޔ⋡ޔญ⣧ౝޔᱤ⡺߅ࠃ߮⢂㐷๟࿐ ߩ∔ᖚߦኻߔࠆዪᚲ⊛૶↪ߪ⑌ᱛߐࠇߕޔ߆ߟᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎ߩ޿߆ߥࠆ↳⺧߽ᔅⷐߣߒߥ޿ޕ

SUBSTANCES PROHIBITED IN PARTICULAR

SPORTS

P1. ALCOHOL

Alcohol (ethanol) is prohibited in-competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) for each Federation is reported in parenthesis.

• Aeronautic (FAI) (0.20 g/L) • Archery (FITA, IPC) (0.10 g/L) • Automobile (FIA) (0.10 g/L) • Boules (CMSB, IPC bowls) (0.10 g/L) • Karate (WKF) (0.10 g/L) • Modern Pentathlon (UIPM) for disciplines involving shooting (0.10 g/L) • Motorcycling (FIM) (0.10 g/L) • Powerboating (UIM) (0.30 g/L)

P2. BETA-BLOCKERS

Unless otherwise specified, beta-blockers are prohibited in-competition only, in the following sports.

• Aeronautic (FAI)

• Archery (FITA, IPC) (also prohibited out-of-competition) • Automobile (FIA)

• Billiards (WCBS) • Bobsleigh (FIBT)

• Boules (CMSB, IPC bowls) • Bridge (FMB)

• Curling (WCF) • Gymnastics (FIG) • Motorcycling (FIM)

• Modern Pentathlon (UIPM) for disciplines involving shooting • Nine-pin bowling (FIQ)

• Sailing (ISAF) for match race helms only

• Shooting (ISSF, IPC) (also prohibited out-of-competition)

• Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air

Υ㧚․ቯ┹ᛛߦ߅޿ߡ⑌ᱛߐࠇࠆ‛⾰

P1. 䉝䊦䉮䊷䊦

ਅ⸥ߩ┹ᛛߦ߅޿ߡޔࠕ࡞ࠦ࡯࡞㧔ࠛ࠲ࡁ࡯࡞㧕ߪ┹ᛛળᬌᩏߦ㒢ߞߡ⑌ᱛߐࠇࠆޕᬌ಴ᣇᴺߪޔ๭ ᳇ಽᨆ߹ߚߪⴊᶧಽᨆߢ޽ࠆޕ࠼࡯ࡇࡦࠣ㆑෻߇ᚑ┙ߔࠆ㑣୯㧔ⴊᶧߩ୯㧕ߪ┹ᛛ࿅૕ߏߣߦ㧔㧕ߢ⴫ ␜ߔࠆޕ ⥶ⓨ䉴䊘䊷䉿䋨࿖㓙⥶ⓨㅪ⋖䋺㪝㪘㪠䋩㩷 䋨㪇㪅㪉㪇㩷㪾㪆㫃䋩㩷 䉝䊷䉼䉢䊥䊷䋨࿖㓙䉝䊷䉼䉢䊥䊷ㅪ⋖䋺㪝㪠㪫㪘䋬࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ䋺㪠㪧㪚䋩㩷 䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷 ⥄േゞ䋨࿖㓙⥄േゞㅪ⋖䋺㪝㪠㪘䋩㩷 䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷 䊑䊷䊦䋨࿖㓙䉴䊘䊷䊦䊶䊄䊶䊑䊷䊦ㅪว䋺㪚㪤㪪㪙䇮࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ㩷 䊨䊷䊮䊗䉡䊦䉴䋺㪠㪧㪚㩷㪹㫆㫎㫃㫊䋩㩷 䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷 ⓨᚻ䋨਎⇇ⓨᚻ㆏ㅪ⋖㪑㪮㪢㪝䋩㩷 䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷 ㄭઍ੖⒳䋨࿖㓙ㄭઍ੖⒳ㅪว䋺㪬㪠㪧㪤䋩኿᠄⒳೎䈮䈍䈇䈩㩷 䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷 䊝䊷䉺䊷䉰䉟䉪䊦䋨࿖㓙䊝䊷䉺䊷䉰䉟䉪䊦ㅪ⋖䋺㪝㪠㪤䋩㩷 䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷 䊌䊪䊷䊗䊷䊃䋨࿖㓙䊌䊪䊷䊗䊷䊃ㅪว䋺㪬㪠㪤䋩㩷 䋨㪇㪅㪊㪇㩷㪾㪆㫃䋩㩷 㩷

P2. 䊔䊷䉺ㆤᢿ⮎

․Ბߩቯ߼߇޽ࠆ႐วࠍ㒰߈ޔࡌ࡯࠲ㆤᢿ⮎ߪޔਅ⸥ߩ┹ᛛ⒳⋡ߦ߅޿ߡ┹ᛛળᬌᩏߦ㒢ߞߡ⑌ᱛߐ ࠇࠆޕ ⥶ⓨ䉴䊘䊷䉿䋨࿖㓙⥶ⓨㅪ⋖䋺㪝㪘㪠䋩㩷 䉝䊷䉼䉢䊥䊷䋨࿖㓙䉝䊷䉼䉢䊥䊷ㅪ⋖䋺㪝㪠㪫㪘䇮࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ䋺㪠㪧㪚䋩㩿┹ᛛᄖ䈮䈍䈇䈩䉅⑌ᱛ䋩㩷 ⥄േゞ䋨࿖㓙⥄േゞㅪ⋖䋺㪝㪠㪘䋩㩷 䊎䊥䊟䊷䊄䋨਎⇇䊎䊥䊟䊷䊄䊶䉴䊘䊷䉿ㅪว䋺㪮㪚㪙㩷 䊗䊑䉴䊧䊷䋨࿖㓙䊗䊑䉴䊧䊷ㅪว䋺㪝㪠㪙㪫䋩㩷 䊑䊷䊦䋨࿖㓙䉴䊘䊷䊦䊶䊄䊶䊑䊷䊦ㅪว䋺㪚㪤㪪㪙䇮࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ㩷 䊨䊷䊮䊗䉡䊦䉴䋺㪠㪧㪚㩷㪹㫆㫎㫃㫊䋩㩷 䊑䊥䉾䉳䋨਎⇇䊑䊥䉾䉳ㅪ⋖䋺㪝㪤㪙䋩㩷 䉦䊷䊥䊮䉫䋨਎⇇䉦䊷䊥䊮䉫ㅪ⋖䋺㪮㪚㪝䋩㩷 ૕ᠲ䋨࿖㓙૕ᠲㅪ⋖䋺㪝㪠㪞䋩㩷 䊝䊷䉺䊷䉰䉟䉪䊦䋨࿖㓙䊝䊷䉺䊷䉰䉟䉪䊦ㅪ⋖䋺㪝㪠㪤䋩㩷 ㄭઍ੖⒳䋨࿖㓙ㄭઍ੖⒳ㅪว䋺㪬㪠㪧㪤䋩኿᠄⒳೎䈮䈍䈇䈩㩷 䊅䉟䊮䊏䊮䊗䉡䊥䊮䉫䋨࿖㓙䊗䉡䊥䊮䉫ㅪ⋖䋺㪝㪠㪨䋩㩷 䉶䊷䊥䊮䉫䋨࿖㓙䉶䊷䊥䊮䉫ㅪ⋖䋺㪠㪪㪘㪝䋩䋭䊙䉾䉼䊧䊷䉴䈮䈍䈔䉎䊓䊦䊛䈱䉂㩷 ኿᠄䋨࿖㓙኿᠄ㅪ⋖䋺㪠㪪㪪㪝䇮࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ䋺㪠㪧㪚䋩䋨┹ᛛᄖ䈮䈍䈇䈩䉅⑌ᱛ䋩㩷 䉴䉨䊷㪆䉴䊉䊷䊗䊷䊄䋨࿖㓙䉴䉨䊷ㅪ⋖䋺㪝㪠㪪䋩䋭䉳䊞䊮䊒䇮䊐䊥䊷䉴䉺䉟䊦䋨䉣䉝䊥䉝䊦㪆䊊䊷䊐䊌䉟䊒䋩䇮㩷 䉴䊉䊷䊗䊷䊄䋨䊊䊷䊐䊌䉟䊒䋯䊎䉾䉫䉣䉝䊷䋩㩷 䊧䉴䊥䊮䉫䋨࿖㓙䊧䉴䊥䊮䉫ㅪ⋖䋺㪝㪠㪣㪘䋩㩷

Beta-blockers include, but are not limited to, the following: acebutolol, alprenolol, atenolol,

betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

ࡌ࡯࠲ㆤᢿ⮎ߣߒߡߪޔਅ⸥ߩ߽ߩ߇฽߹ࠇࠆ߇ޔߎࠇࠄߦ㒢ቯߔࠆ߽ߩߢߪߥ޿ޕ ǢǻȖȈȭȸȫŴǢȫȗȬȎȭȸȫŴǢȆȎȭȸȫŴ șǿǭǽȭȸȫŴȓǽȗȭȭȸȫŴȖȎȭȸȫŴ ǫȫȆǪȭȸȫŴǫȫșǸȭȸȫŴǻȪȗȭȭȸȫŴ ǨǹȢȭȸȫŴ ȩșǿȭȸȫŴȬȜȖȎȭȸȫŴ ȡȁȗȩȎȭȸȫŴȡȈȗȭȭȸȫŴ ȊȉȭȸȫŴ ǪǯǹȗȬȎȭȸȫŴ ȔȳȉȭȸȫŴȗȭȗȩȎȭȸȫŴ ǽǿȭȸȫŴ ȁȢȭȸȫŵ

SPECIFIED SUBSTANCES*

“Specified Substances”* are listed below:

• All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol;

• Probenecid;

• Cathine, cropropamide, crotetamide, ephedrine, etamivan,

famprofazone, heptaminol, isometheptene, levmethamfetamine,

meclofenoxate, p-methylamphetamine, methylephedrine, nikethamide, norfenefrine,

octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine, selegiline, sibutramine,

tuaminoheptane,

and any other stimulant not expressly listed under section S6 for which the Athlete establishes that it fulfils the conditions described in section S6; • Cannabinoids;

• All Glucocorticosteroids; • Alcohol;

• All Beta Blockers.

* “The Prohibited List may identify specified substances which are particularly

susceptible to unintentional anti-doping rule violations because of their general availability in medicinal products or which are less likely to be successfully abused as doping agents.” A doping violation involving such substances may result in a

reduced sanction provided that the “…Athlete can establish that the Use of such a

Φ㧚ᜰቯ‛⾰



_

 ޟᜰቯ‛⾰*ޠߪޔਅ⸥ߩߣ߅ࠅߢ޽ࠆޕ ࡮ ߔߴߡߩๆ౉ࡌ࡯࠲2 ૞↪⮎ޔ㧔1000ng/mLએ਄ߩࠨ࡞ࡉ࠲ࡕ࡯࡞㧔ࡈ࡝࡯ߣࠣ࡞ࠢࡠࡦ㉄ᛴว૕ ߩỚᐲ㧕ߣࠢ࡟ࡦࡉ࠹ࡠ࡯࡞ࠍ㒰ߊ㧕㧧 ࡮ ࡊࡠࡌࡀࠪ࠼㧧 ࡮ ࠞ࠴ࡦޔࠢࡠࡊࡠࡄࡒ࠼ޔࠢࡠ࠹࠲ࡒ࠼ޔ ࠛࡈࠚ࠼࡝ࡦޔࠛ࠲ࡒࡃࡦޔ ࡈࠔࡦࡊࡠࡈࠔ࠱ࡦޔ ࡋࡊ࠲ࡒࡁ࡯࡞ޔ ࠗ࠰ࡔ࠹ࡊ࠹ࡦޔ ࡟ࡉࡔ࠲ࡦࡈࠚ࠲ࡒࡦޔ ࡔࠢࡠࡈࠚࡁࠠ࠮࡯࠻ޔp-ࡔ࠴࡞ࠕࡦࡈࠚ࠲ࡒࡦޔࡔ࠴࡞ࠛࡈࠚ࠼࡝ࡦޔ ࠾ࠤ࠲ࡒ࠼ޔࡁ࡞ࡈࠚࡀࡈ࡝ࡦޔ ࠝࠢ࠻ࡄࡒࡦޔࠝ࡞࠹࠲ࡒࡦޔࠝࠠࠪࡠࡈ࡝ࡦޔ ࡈࠚࡦࡊࡠࡔ࠲ࡒࡦޔࡊࡠࡇ࡞ࡋࠠ࠮࠼࡝ࡦޔ ࠮࡟ࠡ࡝ࡦޔࠪࡉ࠻࡜ࡒࡦޔ ࠷ࠕࡒࡁࡋࡊ࠲ࡦ ෸߮ߘߩઁߩ⥝ᅗ⮎ߢ S6 ߦ᣿⏕ߦ⸥タߐࠇߡ߅ࠄߕޔS6 ߦㅀߴߚ᧦ઙࠍḩߚߔߎߣࠍ┹ᛛ⠪߇⸽ ᣿ߒߚ⮎‛ ࡮ ࠞࡦ࠽ࡆࡁࠗ࠼㧧 ࡮ ߔߴߡߩ♧⾰ࠦ࡞࠴ࠦࠗ࠼㧧 ࡮ ࠕ࡞ࠦ࡯࡞㧧 ࡮ ߔߴߡߩࡌ࡯࠲ㆤᢿ⮎ޕ  ޟ⑌ᱛ࡝ࠬ࠻ߢߪޔක⮎ຠߣߒߡᐢߊᏒ⽼ߐࠇޔᓥߞߡਇᵈᗧߢ࠼࡯ࡇࡦࠣⷙೣ㆑෻ࠍ⿠ߎߒ߿ߔ޿ ⮎‛ޔ޽ࠆ޿ߪ࠼࡯ࡇࡦࠣ‛⾰ߣߒߡߪᲧセ⊛ੂ↪ߐࠇࠆߎߣ߇ዋߥ޿⮎‛ࠍޔ․ߦᜰቯ‛⾰ߣߔࠆߎ ߣ߇ߢ߈ࠆޠޕߘߩࠃ߁ߥ‛⾰ࠍ฽߻࠼࡯ࡇࡦࠣ㆑෻ߢߪޔޟߎߩ⒳ߩᜰቯ‛⾰ߩ૶↪߇┹ᛛജะ਄ࠍ ⋡⊛ߣߒߚ߽ߩߢߥ޿ߎߣࠍ┹ᛛ⠪߇⸽᣿ߢ߈ࠆޠ႐วߦߪ೙ⵙಣ⟎ߪシᷫߐࠇࠆߎߣ߇޽ࠆޕ

THE 2007 MONITORING PROGRAM*

The following substances are placed on the 2007 Monitoring Program:

1. Stimulants: In-Competition Only: Bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradrol, pseudoephedrine,

synephrine.

2. Narcotics: In-Competition Only: morphine/codeine ratio

* The WADA Code (4.5) states: “WADA, in consultation with other Signatories and

governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.”

WORLD

ANTI-DOPING

AGENCY

WORLD

ANTI-DOPING

AGENCY

play true

 

઒⸶

 

 ᐕ⋙ⷞࡊࡠࠣ࡜ࡓ



_

 ਅ⸥ߩ‛⾰߇  ᐕ⋙ⷞࡊࡠࠣ࡜ࡓߦឝタߐࠇࠆޕ  ᲫᲨᐻڠᕤᲴ ᇤ২˟౨௹ƷLj  ࡉࡊࡠࡇࠝࡦޔࠞࡈࠚࠗࡦޔࡈࠚ࠾࡟ࡈ࡝ࡦޔ ࡈࠚ࠾࡞ࡊࡠࡄࡁ࡯࡞ࠕࡒࡦޔࡇࡊ࡜࠼ࡠ࡯࡞ޔࡊ࠰ࠗ࠼ࠛࡈࠚ࠼࡝ࡦޔ ࠪࡀࡈ࡝ࡦ  ᲬᲨ᰺ ᕤᲴ ᇤ২˟౨௹ƷLj  ࡕ࡞ࡅࡀ㧛ࠦ࠺ࠗࡦᲧ   *WADAⷙ⒟㧔4.5᧦㧕㧦⑌ᱛ࡝ࠬ࠻ߦឝタߐࠇߡ޿ߥ޿‛⾰ߩ߁ߜޔ┹ᛛߦ߅ߌࠆ⮎‛ੂ↪ࡄ࠲࡯ࡦࠍ ᛠីߒߚᣇ߇ᓧ╷ߢ޽ࠆߣWADA߇್ᢿߒߚ߽ߩ߇޽ࠆ႐วޔWADAߪޔઁߩ⟑ฬᒰ੐⠪෸߮ฦ࿖᡽ᐭ ߣද⼏ߒߡᒰ⹥‛⾰ߦ㑐ߔࠆ⋙ⷞࡊࡠࠣ࡜ࡓࠍ╷ቯߔࠆ߽ߩߣߔࠆޕ

WORLD

ANTI-DOPING

AGENCY

play true

ޟWADA code ߪ⧷ᢥ ߇ේᧄߣߥࠅ߹ߔޕᧄⷙ⒟ߩ⧷ᢥߣ๺ᢥߦᏅ⇣

߇޽ࠆ႐วߦߪޔ⧷ᢥ߇ఝవߐࠇ߹ߔޕ

ޠ

THE WORLD ANTI-DOPING CODE

The 2007 Prohibited List International Standard

ଲ ٮ ͺ ϋ Ι ¦ Ρ Ȝ ά ϋ Έ ܰ ೾ ! 3118 ා޺গςΑΠͅ۾̳࣭ͥषܖ੔!

2007 ා 1 ࠮ 1 ඾อ࢘ 2007 ᐕ 1 ᦬⊒ⴕ

2007年禁止リスト国際基準

(The 2007 Prohibited List International Standard)

（2007年１月１日版）

(Update 1 January 2007)

本リストは、2007年１月１日に発効する

財団法人 日本アンチ・ドーピング機構

スポーツ振興くじ助成事業

（The World Anti-doping Code）

世界アンチ・ドーピング規程

仮 訳

WORLD

ANTI-DOPING

AGENCY

play true